Peptide therapy clinic good faith exams are the in-person or synchronous telehealth visit a licensed provider completes before a patient starts a peptide protocol, documenting medical history, contraindications, and prescribing rationale before the first vial or injection ships. Peptide clinics carry a different exam load than a filler or Botox practice because they're prescribing compounded, often non-FDA-approved substances (BPC-157, sermorelin, ipamorelin, PT-141, thymosin alpha-1) alongside GLP-1 peptides like tirzepatide and semaglutide, each with its own contraindication checklist.
- Good faith exams for peptide therapy clinics cover compounded peptides and GLP-1 protocols, not just injectable-aesthetic contraindications.
- US Medical Directors documents good faith exams for peptide, tirzepatide, and sermorelin protocols across many states.
- A wellness intake questionnaire alone does not satisfy a good faith exam requirement in states that mandate a licensed exam.
- Budget one good faith exam per new peptide protocol added to a patient’s chart, not one per calendar visit.
Why good faith exams matter for peptide therapy clinics
Most peptides sold through medspas and wellness clinics are compounded at 503A or 503B pharmacies rather than FDA-approved as standalone drugs, which means the prescribing standard falls back on the treating clinician's clinical judgment and documented exam, not an FDA label. State medical boards that require a good faith exam before prescribing typically don't carve out an exception for compounded or off-label substances — the exam requirement attaches to the act of prescribing, not to the regulatory status of the peptide itself.
Peptide protocols also change faster than a typical Botox refill cycle. A patient might start on sermorelin for recovery, add tirzepatide for weight management three months later, and layer in NAD+ within the year. Each addition changes the contraindication profile and, in many states, resets the good faith exam clock. Medical director support for peptide therapy clinics exists specifically because this stacking pattern is common and easy to under-document.
Map which peptides need a good faith exam
Start by inventorying what's actually on the menu before building an exam workflow around it.
- BPC-157 and TB-500 for recovery/injury protocols
- Sermorelin, ipamorelin, and CJC-1295 for growth hormone support
- Tirzepatide and semaglutide for weight management
- PT-141 for sexual wellness
- Thymosin alpha-1 and NAD+ for immune/energy protocols
- Any peptide combined with hormone pellets or testosterone therapy
Every item on that list is a prescription decision, and every prescription decision in a state requiring good faith exams needs one on file before the first dose.
Build the exam intake for compounded peptides
A generic aesthetic intake form misses half of what a peptide exam needs to cover. The exam has to establish medical necessity and rule out contraindications specific to the substance class, not just confirm the patient isn't pregnant or on blood thinners.
- Full medication list, including supplements that interact with GLP-1s or growth hormone peptides
- Personal or family history of medullary thyroid cancer or MEN2 for GLP-1 candidates
- Pancreatitis history for tirzepatide and semaglutide patients
- Active infection or autoimmune flare for immune-modulating peptides like thymosin alpha-1
- Current fertility plans or pregnancy status for hormone-adjacent peptides
- Baseline vitals and, where the protocol calls for it, recent labs
Decide who performs the exam
Most states let a physician, nurse practitioner, or physician assistant complete the exam, but the supervising or collaborating physician still carries responsibility for the standard of care. Clinics running peptide programs under a nurse practitioner or PA need the exam authority spelled out in the collaborating agreement, not assumed.
- Physician on staff performs all exams directly
- NP or PA performs exams under a documented standing order or protocol
- Contracted good faith exam provider performs exams remotely under synchronous telehealth rules
- Collaborating physician reviews and co-signs high-risk cases only
Document the exam in the chart
An undocumented exam is functionally the same as no exam if the clinic gets audited. Chart notes need to show the exam happened, what was reviewed, and why the peptide protocol was clinically appropriate for that specific patient. The same logic that applies to documenting good faith exams for tirzepatide patients applies to every other peptide on the menu.
- Date, method (in-person or synchronous telehealth), and exam duration
- Contraindications reviewed and ruled out, by name
- Peptide, dose, and route prescribed, with rationale tied to the exam findings
- Provider signature and license number on the note
- Follow-up interval documented at the time of the exam, not added later
Set exam cadence and volume
Clinics that scale a peptide program without planning exam volume end up either overstaffing exam slots or falling behind and stacking prescriptions on stale exams. Calculating how many good faith exams a practice needs per month before adding a new peptide line keeps the exam workflow from becoming the bottleneck once demand picks up.
- New patient starts require a fresh exam every time, regardless of prior aesthetic history with the clinic
- Protocol changes (new peptide, new dose tier, new route) typically trigger a new exam
- Refill-only visits on an unchanged protocol may fall under a shorter re-exam interval, set by state rule
- Multi-location clinics need exam volume tracked per site, not pooled across the group
Choose a good faith exam provider or delegate the workflow
Running exams entirely in-house works for a single-location clinic with a physician on staff most days. It gets harder once a peptide clinic adds a second state, launches telehealth intake, or scales past a handful of providers doing injections. Patients on tirzepatide or semaglutide protocols also lose lean mass alongside fat if intake isn't managed well, and clinics that treat the exam as a one-time checkbox miss the chance to fold nutrition guidance into the documented plan; pairing dose titration notes with protein support for GLP-1 patients gives the exam file a stronger clinical rationale than a dosage instruction alone.
- In-house physician handles all exams personally
- Per-visit contracted physician covers exam volume as it comes up
- Telehealth good faith exam service handles exams across multiple states under one workflow
- Untrained front-desk intake substitutes for an exam (not a real option, listed here because clinics still try it)
Audit and refresh exams as protocols change
A peptide chart is never really finished. Every time a patient adds a peptide, changes dose tier, or restarts after a gap, the exam file needs a fresh look.
- Quarterly chart spot-checks against active peptide protocols
- Flag any patient on more than two concurrent peptides for a full re-exam
- Cross-check exam dates against state-mandated re-exam intervals
- Confirm the exam still matches the current prescribing provider's license and scope
Comparison: good faith exam options for peptide clinics
| Option | Best for | Key limitation |
|---|---|---|
| In-house physician on staff | Single-location clinics with daily physician presence | Coverage gaps when the physician is out |
| Per-visit local physician | Low-volume solo peptide practices | Scheduling delays as peptide volume grows |
| Telehealth good faith exam service | Multi-state peptide clinics scaling protocols | Still bound by each state's synchronous telehealth rules |
| Intake form with no licensed exam | No one — listed because clinics still attempt it | Doesn't meet the good faith exam standard in most states |
Verdict: a telehealth good faith exam service built for aesthetic and peptide protocols is the best fit for any clinic operating in more than one state or adding peptides faster than an in-house physician can keep up with exam volume.
Common mistakes peptide therapy clinics make
- Treating the intake questionnaire as the exam. A form the patient fills out alone doesn't satisfy a good faith exam requirement that calls for a licensed provider's clinical assessment.
- Not re-examining when the protocol changes. Moving a patient from sermorelin to tirzepatide changes the contraindication list; the old exam doesn't cover the new prescription.
- Assuming compounded peptides are exempt. Peptides not approved by the FDA still fall under the prescribing physician's duty of care, and most state good faith exam rules follow the prescribing act, not the drug's approval status.
- Losing track of exam expiration across a growing peptide menu. Clinics running four or five peptide lines per patient often lose the thread on which exam covers which protocol.
- Using an out-of-state telehealth provider not licensed where the patient sits. The exam has to be valid in the patient's state, not the provider's home state.
Get exam coverage for your peptide clinic
Good faith exams and physician oversight built for peptide and GLP-1 protocols.
FAQ
What is a good faith exam for a peptide therapy clinic?
It’s the licensed exam a physician, NP, or PA completes before prescribing a peptide, documenting medical history and contraindications specific to that protocol. It has to happen before the first dose, not after.
Do compounded peptides like BPC-157 or sermorelin require a good faith exam?
Yes, in states that mandate a good faith exam before prescribing, the requirement attaches to the act of prescribing, not to whether the substance is FDA-approved. Compounded peptides don’t get an exemption.
Can a nurse practitioner perform the good faith exam for peptide patients?
In most states, yes, if the collaborating physician agreement or standing order explicitly grants that authority. The NP’s scope and the state’s supervision rules both need to line up.
Is a telehealth good faith exam valid for peptide therapy patients?
Many states accept a synchronous telehealth exam for peptide prescribing, but the rules vary by state and by substance class. Check the specific state’s telehealth prescribing statute before relying on it.
How often should a peptide clinic repeat a good faith exam?
A new exam is typically required for each new peptide added or each significant dose change, and many states set a maximum interval for refill-only visits. Track the interval per state, not per clinic policy alone.
Is tirzepatide treated the same as other peptides for exam requirements?
Tirzepatide is compounded like other peptides in many clinics, so the same good faith exam standard applies, with contraindication screening focused on pancreatitis and thyroid cancer history specific to GLP-1 agents.
What’s the difference between a good faith exam and a chart review?
The good faith exam happens before prescribing and establishes medical appropriateness. Chart review happens after treatment and checks that documentation, dosing, and follow-up match the standard of care.
What happens if a peptide clinic skips the good faith exam?
The clinic prescribes without meeting the state’s standard of care, which exposes the practice and the prescribing provider to board discipline and makes the chart indefensible in an audit or complaint.
One last thing
The good faith exam requirement doesn't loosen because a peptide isn't FDA-approved — if anything, boards scrutinize compounded-substance prescribing harder because there's no drug label to point to as the standard of care. The exam and the chart note are the standard of care for a peptide clinic; treat every new peptide added to a patient's plan as a fresh prescribing decision, not a menu upsell, and 2026 audits get a lot less stressful.
Related guides
